TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01620827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Private Cell Phone Calls
Description: Follow-up phone calls are made from the private cell phones of research assistants
Study: NCT02249481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal catheter delivering 0.0625% L- Bupivacaine
Description: Adductor canal catheter: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve catheter delivering 0.0625% L- Bupivacaine
Description: Femoral nerve catheter: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
Study: NCT00915850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCF
Description: docetaxel, Cisplatin and 5-FU
Study: NCT04574245

Intervention type: PROCEDURE
Intervention: Gastrectomy; Hepatectomy
Study: NCT03614832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Description: half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 150 mg
Description: double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
Study: NCT03833011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulation
Description: Osteopathic manipulation
Study: NCT02028910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.~The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.~The dosage should be adjusted according to the weight of the child

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.~The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.~The dosage should be adjusted according to the weight of the child
Study: NCT03427229

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Single-infusion FMT
Description: Patients will receive a single fecal infusion by colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin (before randomization)
Description: Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin (before randomization)
Description: Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multiple-infusion FMT
Description: Patients will receive multiple fecal infusions by colonoscopy
Study: NCT01452672

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT 40 Gy in 15 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Irradiation of the chest-wall and supraclavicular fossa
Description: RT 40Gy in 15 fractions
Study: NCT01884974

Intervention type: OTHER
Intervention: myeloproliferative disease
Description: Echocardiogram, demographic data, St George respiratory questioner
Study: NCT04438811

Intervention type: OTHER
Group type: OTHER
Intervention: delivery of the spinal anesthetic by a trained medical officer
Description: The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: delivery of spinal anesthetic by a consultant anesthetist
Description: The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
Study: NCT04034238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: Arms 1 and 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: Arms 1 and 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Arms 1 and 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Arms 1 and 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesothelin Expression
Description: Test for mesothelin expression in tumor tissues for study eligibility
Study: NCT04729543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive therapy with autologous MC2 TCR T cells
Description: Adoptive therapy with autologous MC2 TCR T cells combined with AZA/VP
Study: NCT03992638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leucocyte and platelet-rich fibrin (L-PRF) in combination with CAF
Description: Completing root coverage by coronally advanced flap technique in combination with L-PRF.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF
Description: Completing root coverage by coronally advanced flap technique alone
Study: NCT01955382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actidose Aqua
Description: Actidose Aqua (oAC) (Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artesunate
Description: Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Description: Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amodiaquine
Description: Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.
Study: NCT03324685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: BIIB074 is administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC (ethinyl estradiol and levonorgestrel)
Description: OC is administered as specified in the treatment arm.
Study: NCT02705911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise
Description: Participants have to perform 4 x 2 minute contractions with alternating hands, separated with 1 minute rest period using a ZonaHealth device;

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic endurance training
Description: To perform 150 minutes extra/week at moderate aerobic intensity
Study: NCT03563560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicine
Description: 60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7
Study: NCT01535911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)
Description: Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
Study: NCT03243760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-2
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
Study: NCT01419847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclopirox

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01518257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
Study: NCT01936012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg tablets of PT Dexa Medica
Description: Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia
Description: Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Study: NCT01869556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergot
Description: Ergot 0.25mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboprost
Description: Carboprost 0.25mg IM
Study: NCT03367013

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Lactoferrin
Description: Intervention includes a daily dose of 200 mg/kg bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Bovine Lactoferrin added
Description: Control includes daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
Study: NCT04265287

Intervention type: OTHER
Intervention: Data collection
Description: Demographic, clinical, microbiological, critical care support and management data will be collected.
Study: NCT01279109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social network building intervention
Description: Group support and 12 weekly health education/skills building sessions during pregnancy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home visit
Description: Three home visits during pregnancy focused on providing education on infant injury prevention
Study: NCT01806311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan32mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan32mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine10mg
Study: NCT02587806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow-Derived Mononuclear Stem Cells
Description: Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberation therapy
Study: NCT03171324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Supplement
Description: 2 mg/kg/day elemental iron
Study: NCT04129762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet without NCS
Description: A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will not contain products with NCS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet without NCS
Description: A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will not contain products with NCS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet with NCS
Description: A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will contain products with NCS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet with NCS
Description: A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will contain products with NCS.
Study: NCT05213403

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation with new scoring system
Description: Evaluate whether patients who have received surgery in line with the developed scoring system have a better aesthetic and oncological outcomes

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation with new scoring system
Description: Evaluate whether patients who have received surgery in line with the developed scoring system have a better aesthetic and oncological outcomes
Study: NCT04282746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54135419
Description: Single dose of JNJ-54135419 oral solution will be administered sublingually.
Study: NCT01471262

Intervention type: PROCEDURE
Intervention: Right hepatectomy
Description: Right liver resection

Intervention type: PROCEDURE
Intervention: Right hepatectomy
Description: Right liver resection
Study: NCT06708923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention Name: Acupuncture Therapy Before and After Embryo Transfer Description: The intervention involves acupuncture therapy performed at two key time points during the IVF cycle: 25 minutes be
Description: Acupuncture Therapy Before and After Embryo Transfer~This intervention consists of acupuncture sessions designed to support implantation and improve pregnancy outcomes during frozen embryo transfer (FET) cycles.~Procedure:~Acupuncture is performed using sterile, single-use needles by certified practitioners trained in reproductive health.~Sessions occur at two critical time points:~Before Embryo Transfer: A 25-minute session targeting acupoints such as Baihui (DU20), Guanyuan (CV4), and Sanyinjiao (SP6) to enhance endometrial receptivity and reduce stress.~After Embryo Transfer: A second 25-minute session targeting acupoints such as Zusanli (ST36) and Taichong (LR3) to promote implantation and relaxation.~Purpose:~Improve uterine blood flow and receptivity. Regulate hormonal balance to optimize the implantation environment. Reduce psychological stress associated with IVF procedures. This intervention is compared retrospectively to standard IVF protocols without acupuncture to asses
Study: NCT03171324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Supplement
Description: 2 mg/kg/day elemental iron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Supplement
Description: 2 mg/kg/day elemental iron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Supplement
Description: 2 mg/kg/day elemental iron
Study: NCT03786770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection
Study: NCT04158687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Administered as powder for oral solution.
Study: NCT03638180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: BLU-5937 oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: BLU-5937 oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to BLU-5937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to BLU-5937
Study: NCT03148275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO